Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484250 | 0.87 | AKR1B1 (0.52) | AKR1B1IDO1AHRCMA1PDE7A | |
| SCHEMBL22904106 | 0.80 | CA9 (0.44) | AKR1B1MEN1KMT2AGAA | |
| SCHEMBL22904130 | 0.80 | CMA1 (0.45) | AKR1B1AHRCMA1MEN1KMT2A | |
| SCHEMBL2480451 | 0.79 | PDE7A (0.47) | AKR1B1IDO1AHRCMA1PDE7A | |
| SCHEMBL4387328 | 0.76 | PDE7A (0.48) | AKR1B1PDE7APGR | |
| SCHEMBL10834099 | 0.75 | PDK2 (0.50) | AKR1B1IDO1MEN1KMT2AGAA | |
| SCHEMBL19260231 | 0.75 | AHR (0.54) | AKR1B1IDO1AHRCMA1PDE7A | |
| SCHEMBL16166247 | 0.75 | AKR1B1 (0.40) | AKR1B1IDO1MEN1KMT2AMGAM | |
| SCHEMBL16166401 | 0.75 | AKR1B1 (0.40) | AKR1B1IDO1MEN1KMT2AMGAM | |
| SCHEMBL16166534 | 0.74 | AKR1B1 (0.39) | AKR1B1IDO1MEN1KMT2AMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8236963-B2 | Tricyclic spiro derivatives as CRTH2 modulators | MERCK SERONO SA (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-1891075-B1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO SA (CH) | 2011-10-19 | — | — | EP | disclosed |
| EP-1891075-B1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO SA (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | LABORATOIRES SERONO S.A. (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-1891075-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125784-A1 | TRICYCLIC SPIRO DERIVATIVES AS CRTH2 MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-4523021-A | ANTIDIABETIC AND ANTIGLACTOSEMIA AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| EP-0065407-B1 | PHARMACEUTICAL SPIRO-SUCCINIMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-13 | — | — | EP | disclosed |
| US-4478847-A | ALDOSE REDUCTASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0065407-A2 | Pharmaceutical spiro-succinimide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318486-A1 | Tricyclic spiro derivatives as CRTH2 modulators | RORB, NR3C2, NR1H2 | AKR1B1 109/4885IDO1 1371/4885AHR 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.